| An intra-tumoral niche maintains and differentiates stem-like CD8 T cells CS Jansen, N Prokhnevska, VA Master, MG Sanda, JW Carlisle, MA Bilen, ... Nature 576 (7787), 465-470, 2019 | 593 | 2019 |
| EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer KL Morel, AV Sheahan, DL Burkhart, SC Baca, N Boufaied, Y Liu, X Qiu, ... Nature cancer 2 (4), 444-456, 2021 | 138 | 2021 |
| Low abundance of circulating tumor DNA in localized prostate cancer ST Hennigan, SY Trostel, NT Terrigino, OS Voznesensky, RJ Schaefer, ... JCO precision oncology 3, 2019 | 68 | 2019 |
| Nascent prostate cancer heterogeneity drives evolution and resistance to intense hormonal therapy S Wilkinson, H Ye, F Karzai, SA Harmon, NT Terrigino, DJ VanderWeele, ... European urology 80 (6), 746-757, 2021 | 53 | 2021 |
| Local alignment vectors reveal cancer cell-induced ECM fiber remodeling dynamics B Lee, J Konen, S Wilkinson, AI Marcus, Y Jiang Scientific reports 7 (1), 39498, 2017 | 42 | 2017 |
| LKB1 kinase-dependent and-independent defects disrupt polarity and adhesion signaling to drive collagen remodeling during invasion J Konen, S Wilkinson, B Lee, H Fu, W Zhou, Y Jiang, AI Marcus Molecular biology of the cell 27 (7), 1069-1084, 2016 | 37 | 2016 |
| Sequential prostate magnetic resonance imaging in newly diagnosed high-risk prostate cancer treated with neoadjuvant enzalutamide is predictive of therapeutic response F Karzai, SM Walker, S Wilkinson, RA Madan, JH Shih, MJ Merino, ... Clinical Cancer Research 27 (2), 429-437, 2021 | 26 | 2021 |
| A case report of multiple primary prostate tumors with differential drug sensitivity S Wilkinson, SA Harmon, NT Terrigino, F Karzai, PA Pinto, RA Madan, ... Nature communications 11 (1), 837, 2020 | 26 | 2020 |
| A subset of localized prostate cancer displays an immunogenic phenotype associated with losses of key tumor suppressor genes C Calagua, M Ficial, CS Jansen, T Hirz, L Del Balzo, S Wilkinson, R Lake, ... Clinical Cancer Research 27 (17), 4836-4847, 2021 | 24 | 2021 |
| Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood JW Carlisle, CS Jansen, MA Cardenas, E Sobierajska, AM Reyes, ... Journal for Immunotherapy of Cancer 10 (7), 2022 | 20 | 2022 |
| MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity NC Whitlock, SY Trostel, S Wilkinson, NT Terrigino, ST Hennigan, R Lake, ... Oncogene 39 (34), 5663-5674, 2020 | 18 | 2020 |
| Assessment of Androgen Receptor splice variant-7 as a biomarker of clinical response in castration-sensitive prostate cancer AG Sowalsky, I Figueiredo, RT Lis, I Coleman, B Gurel, D Bogdan, ... Clinical Cancer Research 28 (16), 3509-3525, 2022 | 12 | 2022 |
| Modeling androgen deprivation therapy–induced prostate cancer dormancy and its clinical implications X Dong, H Xue, F Mo, Y Lin, D Lin, NKY Wong, Y Sun, S Wilkinson, AT Ku, ... Molecular Cancer Research 20 (5), 782-793, 2022 | 11 | 2022 |
| Defining cellular population dynamics at single-cell resolution during prostate cancer progression AA Germanos, S Arora, Y Zheng, ET Goddard, IM Coleman, AT Ku, ... Elife 11, e79076, 2022 | 10 | 2022 |
| Coordinated cell motility is regulated by a combination of LKB1 farnesylation and kinase activity S Wilkinson, Y Hou, JT Zoine, J Saltz, C Zhang, Z Chen, LAD Cooper, ... Scientific reports 7 (1), 40929, 2017 | 9 | 2017 |
| LKB1 promotes cell survival by modulating TIF-IA-mediated pre-ribosomal RNA synthesis under uridine downregulated conditions F Liu, R Jin, X Liu, H Huang, SC Wilkinson, D Zhong, FR Khuri, H Fu, ... Oncotarget 7 (3), 2519, 2016 | 8 | 2016 |
| Comparison of approaches to transcriptomic analysis in multi-sampled tumors AT Ku, S Wilkinson, AG Sowalsky Briefings in Bioinformatics 22 (6), bbab337, 2021 | 7 | 2021 |
| Synthetic lethality-based prediction of cancer treatment response from histopathology images DT Hoang, G Dinstag, LC Hermida, DS Ben-Zvi, E Elis, K Caley, S Sinha, ... Preprint at bioRxiv 495219, 2022 | 6* | 2022 |
| Progression of prostate cancer reprograms MYC-mediated lipid metabolism via lysine methyltransferase 2A NC Whitlock, ME White, BJ Capaldo, AT Ku, S Agarwal, L Fang, ... Discover Oncology 13 (1), 97, 2022 | 3 | 2022 |
| AR inhibition increases MHC class I expression and improves immune response in prostate cancer LN Chesner, JN Graff, F Polesso, A Smith, A Lundberg, R Das, T Shenoy, ... | 2 | 2023 |
